Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab for Pediatric CNI-Resistant/Intolerant SRNS
NCT06607991Phase 1Recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of blinatumomab in nephrotic syndrome, sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoint: Rate of complete or partial remission of proteinuria at 24 weeks. Started Sep 2024; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT06607991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607991.